Promising Pancreatic Cancer Trial Enrolling Patients at Columbia

by Columbia Surgery on October 18, 2011

Kenneth P. Olive, PhD

Kenneth P. Olive, PhD

NewYork-Presbyterian Hospital/Columbia University Medical Center is participating in an important trial of a new drug known as IPI-926 that could improve survival outcomes in patients with metastatic pancreatic cancer. Kenneth P. Olive, PhD, Assistant Professor of Medicine and Pathology and member of the Pancreas Center, led the original basic science study that provided the scientific foundation for the clinical use of this drug.

According to Dr. Olive, pancreatic tumors build protective walls around themselves that prevent chemotherapy from getting into the tumor. IPI-926 works by inhibiting a tumor’s ability to build and maintain that wall. With this wall weakened, already existing therapies could prove much more effective, doing more damage to the cancer and less to the patient. If it turns out that other cancers behave in a similar manner, IPI-926 could potentially improve the outcomes of tens of thousands of cancer patients around the world — which explains the excitement that the latest developments in IPI-926 research generated when presented at the American Society of Clinical Oncology (ASCO) in early June.

An early trial designed primarily to test the toxicity of IPI-926 in combination with gemcitabine (the national standard-of-care treatment for pancreatic cancer) found a very positive early outcome. In this Phase I-b trial, 31% of patients with metastatic pancreatic cancer had partial responses after treatment with IPI-926 + gemcitabine, which compares favorably with the historical rate of 5% in patients treated with gemcitabine alone. Even more notably, the regimen was extremely well-tolerated with very little additional toxicity over gemcitabine alone.

With these early promising results, Infinity Pharmaceuticals, the company behind the IPI-926 research, is now conducting a larger Phase II trial across 29 institutions to further evaluate the drug’s efficacy. M. Wasif Saif, MD, MBBS, and Dr. Olive are directing the NYP/Columbia arm of this 118-patient, randomized, double-blind trial.

It’s still too early to say what the results of this important study will be, but Dr. Olive believes that the level of hope in the pancreatic cancer research field is higher than it has been in many years. Pancreatic cancer outcomes have scarcely improved in the past 40 years — but that may soon change, he says. “This is an extremely dynamic and exciting time in pancreatic cancer research. There is so much happening right now, and this is one example. There are many other investigative drugs working their way through research pipeline and into the clinical trial process. My level of hope and enthusiasm for a breakthrough in pancreatic cancer is tremendously elevated. We are starting to make inroads against this devastating disease, which has not been true for decades.”

{ 3 comments… read them below or add one }

Margie S April 20, 2013 at 6:46 pm

My 50 year old daughter has been diagnosed with this horrible disease. I am praying with God’s favor, that she will be able to be admitted into the research facility at Columbia under Dr. Fine.

She was admitted into the center on April 19th 2013. She has had no other treatment except at Columbia. I found her former medical affiliations very lacking and incompetent. I feel very safe with her being in the hands of Dr. Fine with his knowledge and expertise in this field.

I thank God that He has blessed us to be considered for the program.

Margie S

Columbia Surgery April 22, 2013 at 10:28 am

Hi Margie,

Thank you for reaching out to us. I have forwarded your comment and contact information to the Pancreas Center. As soon as I hear a response from them, I will reply.

To contact the Pancreas Center directly, you may reach them at: 212-305-9467. You may also learn more about the Pancreas Center by visiting: http://pancreasmd.org

Columbia Surgery April 30, 2013 at 10:14 am

Margie,

Generally as each case is different, the Pancreas Center requests that they are contacted directly. They would be glad to review the patients records and get back to you as soon as possible. The records can be faxed to 212-305-1571. If you have any further questions please feel free to contact the New Patient Coordinators Lynette or Priscilla at 212-305-9467.

You may also contact Dr. Fine’s office directly at: 212-305-1168. Further information can be found via his profile at: http://www.cumc.columbia.edu/hematology-oncology/about_us/robert_fine

Leave a Comment

Previous post:

Next post: